Consolidation #4(with daunorubicin)

Phase 2Small molecule

YYonsei University

Consolidation #4(with daunorubicin) is one of 2 small molecule programs targeting Lymphoid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphoidRecruiting

LymphoidPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Lymphoid

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 1

2 2

Consolidation #4(with daunorubicin)

YYonsei University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 2Recruiting

Lymphoid

NCT06516679

Clinical

Trials by Indication[1]

Lymphoid1 trial

Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia: A Multicenter, Prospective Study

Recruiting·YYonsei University·Phase 2·NCT06516679·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Consolidation #4(with daunorubicin). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidation #4(with daunorubicin) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidation #4(with daunorubicin). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: YYonsei University

Consolidation #4(with daunorubicin)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Lymphoid1 trial

References

Drug Info

Quick Facts

Related News